Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maternal third-trimester pneumococcal conjugate vaccination and infant pneumococcal IgG levels
PACTR202102724115194Phase 1Recruiting
- Sponsor
- Akinola Ayodeji
- Start
- Jan 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of pneumococcal conjugate vaccine and tetanus toxoid in pneumococcal disease (2 arms), sponsored by Akinola Ayodeji. Primary endpoint: Serum pneumococcal IgG levels in infants. Started Jan 2021; status: recruiting.
02
Drugs
pneumococcal conjugate vaccinetetanus toxoid
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on PACTR202102724115194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202102724115194.